Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT05458674 Recruiting - Breast Cancer Clinical Trials

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo and recurrent unresectable metastatic HER-2/neu positive breast cancer as assessed by ORR, PFS and OS after prior treatment with a taxane, trastuzumab, and T-DM1.

NCT ID: NCT05458284 Recruiting - Breast Cancer Clinical Trials

The Effect of Acupuncture on Nerve Pain Caused by Taxane (Chemotherapy) Treatment

Start date: July 11, 2022
Phase: Phase 2
Study type: Interventional

Some people experience a side effect while they are receiving taxane called taxane-induced peripheral neuropathy (TIPN). TIPN is pain in the arms and legs due to nerve damage caused by cancer treatment and may interfere with quality of life. The purpose of this study is to learn if acupuncture can prevent TIPN from getting worse. Acupuncture is a medical technique that involves insertion of very thin needles into specific areas on the body. We will compare real acupuncture (RA) to placebo (sham) acupuncture (SA). SA is done like RA, but will use different needles and target different sites or places on the body than RA. We are comparing RA to SA to learn whether RA can prevent TIPN from getting worse while receiving taxane.

NCT ID: NCT05456373 Recruiting - Breast Cancer Clinical Trials

Intraoperative Use of ClearEdge Device in Breast Conserving Surgery

Start date: October 10, 2022
Phase: N/A
Study type: Interventional

Multi center, pivotal prospective, randomized clinical trial The proposed randomized controlled study will evaluate the benefits of adding the ClearEdge imaging device to the Standard of Care (SoC) of margins assessment in breast conserving surgeries. The study will assess whether there is an improvement in the detection of DCIS or invasive cancer involved margins by measuring whether removal at the time of primary surgical treatment can reduce the need for repeat surgeries as compared to the SoC, which does not use the device.

NCT ID: NCT05454553 Recruiting - Breast Cancer Clinical Trials

Efficacity of Deep Inspiration Breath Hold and Intensity-modulated Radiotherapy in Preventing PErfusion Defect for Left Sided Breast Cancer (EDIPE)

EDIPE
Start date: October 27, 2022
Phase: N/A
Study type: Interventional

Breast irradiation is known to cause radiation-induced heart disease (RIHD) many years later after radiotherapy. Recent studies suggest that RIHD could be an earlier complication and that subclinical cardiac injury can be detected such as myocardial perfusion defects. Myocardial perfusion single photon emission computed tomography (SPECT) is a sensitive and specific technique able to detect perfusion abnormalities which are more frequent in left-sided breast cancer patients because of the cardiac exposure. The most used technique for breast cancer irradiation is tangential opposed field, but this technique exposes the left anterior descending coronary artery to high dose during left breast irradiation. There are different cardiac sparing techniques to reduce heart exposure such as: - Deep inspiration breath-hold (DIBH) which displaces the heart out of the radiation beam - Intensity-modulated radiation therapy (IMRT) which decreases heart exposure to high doses but changes the dose distribution in the heart and increases lower doses.

NCT ID: NCT05453591 Recruiting - Breast Cancer Clinical Trials

Investigation of Urinary Biomarkers for the Detection of Breast Cancer

URODETECT-WP3
Start date: December 21, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to investigate and possibly validate urinary biomarkers for breast cancer. During this study the focus will be on aberrations of selected genes as prognostic or predictive value has been shown for these genes in tissue, CTC or blood derived cfDNA. Proteins will be explored in urine as well. This is a prospective study in which urine samples will be collected from healthy volunteers and urine samples and a blood sample from cancer patients with breast cancer. The participants will be asked to provide a urine sample collected with the ColliPee® device and fill out an online questionnaire to collect usability data. Thereafter, the urine sample will be aliquoted to be used in the study to investigate the different urinary analytes.

NCT ID: NCT05452681 Recruiting - Breast Cancer Clinical Trials

A QoL Intervention for Young African American Breast Cancer Survivors

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this two-arm pilot RCT is to evaluate processes and preliminary outcomes of a targeted QOL intervention vs. an attention control among young AA survivors post-treatment for early (I-II) & late (III) stage breast cancer.

NCT ID: NCT05452213 Recruiting - Breast Cancer Clinical Trials

Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

CAPTOR-BC
Start date: October 12, 2022
Phase: Phase 4
Study type: Interventional

This is a single-arm, open-label phase IV study of patients with advanced HR+/HER2- breast cancer who are treated first line with ribociclib and standard of care endocrine treatment according to SmPC.

NCT ID: NCT05450016 Recruiting - Breast Cancer Clinical Trials

Assessment of the Breast Cosmesis Using Deep Neural Networks: an Exploratory Study (ABCD)

ABCD
Start date: October 4, 2021
Phase:
Study type: Observational

Surgery and radiotherapy in breast cancer patients can cause treatment changes and may affect the final breast appearance. In this study, we are trying to evaluate the post treatment breast photographs of the patients and subject these to Artificial Intelligence based program so as to classify into appropriate categories based upon changes from baseline. This automated solution will help in decreasing the time required to achieve this task by physicians in the clinic.

NCT ID: NCT05449691 Recruiting - Breast Cancer Clinical Trials

Biological Matrices Versus Synthetic Meshes

BIOSYM
Start date: November 2, 2023
Phase: N/A
Study type: Interventional

In this feasibility study, 60 women undergoing reconstruction will be randomly allocated to receive biological or synthetic mesh and followed for 6 months. The findings will tell us if patients and surgeons are comfortable with not being able to choose which mesh is used for the operation. In the larger surgical study, the investigators plan to measure patients' satisfaction with the reconstruction, patients' quality of life, complications from the operation and costs over 5 years.

NCT ID: NCT05447988 Recruiting - Breast Cancer Clinical Trials

Motiva Flora Tissue Expander PMCF

Start date: December 14, 2020
Phase: N/A
Study type: Interventional

The Motiva Flora® Tissue Expander clinical study (hereafter Motiva Flora® TE study) is a 6-month, open-label, prospective, multicentre post-marketing follow-up study designed to confirm the Safety and Effectiveness/Performance of Motiva Flora® TE in breast reconstruction surgery. The study will include 136 women, planned for staged breast reconstruction, in 6 countries (Spain, Belgium, France, Costa Rica, Chile and Panama). Breast tissue expansion and the final breast implant will be performed using devices from the Motiva Flora® TE catalogue.